Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-21

Clinical Trial Update: The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating BEVESPI AEROSPHERE (glycopyrrolate/formoterol fumarate) on exercise tolerance in chronic obstructive pulmonary disease has completed. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevespi Aerosphere (glycopyrrolate/formoterol fumarate)

Snippet

Sponsor: William Stringer, md | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2025-10-21